Short Interest in Novavax Expands By 6.2% (NVAX)
Shares of Novavax (NASDAQ:NVAX) saw a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 28,597,396 shares, an increase of 6.2% from the July 15th total of 26,917,096 shares, Analyst Ratings.Net reports. Based on an average trading volume of 2,792,251 shares, the days-to-cover ratio is currently 10.2 days. Approximately 12.9% of the company’s shares are short sold.
Separately, analysts at FBR Capital Markets cut their price target on shares of Novavax from $11.00 to $10.00 in a research note on Thursday, August 7th. They now have an “outperform” rating on the stock. Six research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $10.50.
Novavax (NASDAQ:NVAX) opened at 4.47 on Tuesday. Novavax has a 52-week low of $2.27 and a 52-week high of $6.95. The stock has a 50-day moving average of $4.50 and a 200-day moving average of $4.80. The company’s market cap is $1.064 billion.
Novavax (NASDAQ:NVAX) last announced its earnings results on Wednesday, August 6th. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.07) by $0.01. The company had revenue of $8.26 million for the quarter, compared to the consensus estimate of $8.74 million. During the same quarter in the prior year, the company posted ($0.08) earnings per share. The company’s quarterly revenue was up 134.0% on a year-over-year basis. On average, analysts predict that Novavax will post $-0.28 earnings per share for the current fiscal year.
Novavax, Inc (NASDAQ:NVAX), is a clinical stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.